Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.03.19	Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s "Investments for the Future” Programme (Businesswire)
05.03.19	Transgene to start clinical development of lead myvacTM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC (Businesswire)
20.12.18	Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients (Businesswire)
17.12.18	Transgene Announces Financial Calendar for 2019 (Businesswire)
05.12.18	Transgene Announces Upcoming Investor Meetings (Businesswire)
12.11.18	Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018 (Businesswire)
07.11.18	Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-Development of a Next-Generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody (Businesswire)
07.11.18	Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference (Businesswire)
30.10.18	NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform (Businesswire)
25.10.18	Transgene : €26.6 Million in Cash and Cash Equivalents as of September 30, 2018 (Businesswire)
17.10.18	First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors (Businesswire)
10.10.18	Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018 (Businesswire)
02.10.18	Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference (Businesswire)
24.09.18	Transgene Unveils myvacTM, an Individualized Immunotherapy against Solid Tumors (Businesswire)
19.09.18	Transgene Presents 2018 Half-Year Results and Business Update (Businesswire)
03.09.18	Transgene Announces Upcoming Investor Meetings (Businesswire)
20.08.18	Transgene Completes the Sale of the Greater China Rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 Million in Newly-Issued Shares (Businesswire)
10.07.18	Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene’s Virus-Based Immunotherapies TG6002 and TG1050 in Greater China (Businesswire)
04.06.18	Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration (Businesswire)
24.05.18	Transgene Announces Upcoming Investor Meetings (Businesswire)
23.05.18	Transgene: Combined General Meeting of May 23, 2018 (Businesswire)
17.05.18	Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018 (Businesswire)
02.05.18	Transgene: Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018 (Businesswire)
26.04.18	Transgene: €35.6 Million in Cash and Cash Equivalents as of March 31, 2018 (Businesswire)
18.04.18	Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018 (Businesswire)
21.03.18	Transgene to Announce Major Clinical Results in 2018 and Achieve Promising Progress on Its New Oncolytic Viruses (Businesswire)
15.03.18	Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018 (Businesswire)
17.01.18	First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology) (Businesswire)
16.01.18	First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC) (Businesswire)
03.01.18	Half-Year Report on the Transgene Liquidity Contract with Kepler Cheuvreux (Businesswire)
21.12.17	Transgene Announces Financial Calendar for 2018 (Businesswire)
18.12.17	Transgene Announces Upcoming Investor Meetings (Businesswire)
06.12.17	BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors (Businesswire)
09.11.17	Transgene Launches a Capital Increase by Way of an Accelerated Book-Build Offering (Businesswire)
30.10.17	Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017 (Businesswire)
26.10.17	Transgene: First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma (Businesswire)
23.10.17	TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis B (Businesswire)
19.10.17	Transgene: Third Quarter Marked by Progress in Clinical Development and Research (Businesswire)
17.10.17	Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B (Businesswire)
12.10.17	Transgene: Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors (Businesswire)
02.10.17	Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors (Businesswire)
21.09.17	Transgene Launches Invir.IOTM, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses (Businesswire)
19.09.17	Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers (Businesswire)
19.09.17	Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers (Businesswire)
13.09.17	Transgene: Availability of the Half-Year Financial Report as Of June 30, 2017 (Businesswire)
13.09.17	Transgene: First Half-Year 2017 in Line with Our Objectives: All Clinical Programs Progressing and New Collaboration Agreements Signed (Businesswire)
11.09.17	Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC) (Businesswire)
07.09.17	Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress (Businesswire)
31.08.17	Transgene Announces Upcoming Investor Meetings (Businesswire)
31.07.17	Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten